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Noncompaction of the ventricular myocardium (NVM) is the morphological hallmark of a rare familial or sporadic unclassified
heart disease of heterogeneous origin. NVM results presumably from a congenital developmental error and has been traced
back to single point mutations in various genes. The objective of this study was to determine the underlying genetic defect in
a large German family suffering from NVM. Twenty four family members were clinically assessed using advanced imaging
techniques. For molecular characterization, a genome-wide linkage analysis was undertaken and the disease locus was
mapped to chromosome 14ptel-14q12. Subsequently, two genes of the disease interval, MYH6 and MYH7 (encoding the a- and
b-myosin heavy chain, respectively) were sequenced, leading to the identification of a previously unknown de novo missense
mutation, c.842G.C, in the gene MYH7. The mutation affects a highly conserved amino acid in the myosin subfragment-1
(R281T). In silico simulations suggest that the mutation R281T prevents the formation of a salt bridge between residues R281
and D325, thereby destabilizing the myosin head. The mutation was exclusively present in morphologically affected family
members. A few members of the family displayed NVM in combination with other heart defects, such as dislocation of the
tricuspid valve (Ebstein’s anomaly, EA) and atrial septal defect (ASD). A high degree of clinical variability was observed, ranging
from the absence of symptoms in childhood to cardiac death in the third decade of life. The data presented in this report
provide first evidence that a mutation in a sarcomeric protein can cause noncompaction of the ventricular myocardium.
Citation: Budde BS, Binner P, Waldmu ¨ller S, Ho ¨hne W, Blankenfeldt W, et al (2007) Noncompaction of the Ventricular Myocardium Is Associated with a
De Novo Mutation in the b-Myosin Heavy Chain Gene. PLoS ONE 2(12): e1362. doi:10.1371/journal.pone.0001362
INTRODUCTION
Cardiomyopathies are diseases of the heart associated with cardiac
dysfunction of variable severity and prognosis. They have in the
past been classified mainly based on morphological, but also on
functional criteria. The terms ‘‘hypertrophy’’ or ‘‘dilatation’’ of the
ventricles were used early to distinguish the most frequent types of
cardiomyopathy. ‘‘Restriction’’ of ventricular filling and ‘‘arrhyth-
mogenesis’’ with progressive loss of myocardial tissue described, in
functional terms, the less frequent classes of cardiomyopathies. A
generally accepted scheme of classifying these disorders was
published by a World Health Organization (WHO) panel in 1995
[1]. Developments since then regarding newly discovered causes
and advanced discrimination of phenotypes have caused an expert
panel in the US to propose an update of previous definitions by
stating that these diseases constitute ‘‘a heterogeneous group of
myocardial disorders associated with mechanical and/or electrical
dysfunction......due to a variety of causes that are frequently
genetic’’ (for reference see [2]). These diseases have long been
divided into ‘‘primary’’ and ‘‘secondary’’ cardiomyopathies.
Primary cardiomyopathies (genetic or nongenetic) are predomi-
nantly confined to heart muscle. Secondary cardiomyopathies
exhibit myocardial dysfunction in conjunction with a large variety
of acquired or inherited systemic diseases. The case presented in
this report belongs to the class of primary cardiomyopathies.
To briefly characterize the major members of this class, the
most frequent disorder is ‘‘hypertrophic cardiomyopathy’’ (HCM
[MIM 192600]) typically involving a hypertrophic, nondilated left
ventricle often associated with left-ventricular outflow tract
obstruction. Heart failure symptoms-with a relatively high risk of
sudden cardiac death-develop usually in young adults or later in life.
HCM has been traced to a variety of mutations in genes encoding
contractile proteins of the cardiac sarcomere. Most commonly
affected are the genes for ß-myosin heavy chain and for myosin-
binding protein C. Nine other sarcomeric genes contribute less
frequently to HCM. More than 250 different autosomal dominant
mutations (probably many more, not all are published) have been
identified in patients and families (for a recent review see [3]).
A typical feature of ‘‘dilated cardiomyopathy’’ (DCM [MIM
115200]) (with genetic or nongenetic causes) is ventricular
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hallmarks are progressive heart failure due to a gradual loss of left-
ventricular contractile function coupled with a high risk of sudden or
heart failure-related death. Up to 35% of DCM cases have been
reported as familial linked to more than 20 genomic loci and genes.
The predominant mode of transmission is autosomal dominant. X-
linked, autosomal recessive or mitochondrial inheritance are less
frequent. Several mutated genes code for the same contractile
proteins that otherwise cause HCM. Other genes encode Z-disc
binding proteins, sarcolemmal and nuclear envelope components
and transcriptional coactivators. Regarding genetic causes, overlap
exists not only with HCM, but also with X-linked cardioskeletal
myopathies in children (for a recent review see [4]).
‘‘Arrhythmogenic right-ventricular cardiomyopathy/dysplasia’’
(ARVC/D [MIM 609040], a rare disorder) has a broad clinical
spectrum usually presenting with ventricular tachyarrhythmia,
syncopes, even cardiac arrest. This condition is often not easily
diagnosed. A sensitive marker is a biopsy from the right ventricle
exposing fibrofatty infiltrations with interspersed strands of myocytes.
Inheritance is autosomal dominant in most cases. Four genes
associated with ARVC/D have been detected involving intermediate
filaments and desmosomes and the calcium release channel RyR2 in
the myocardial sarcoplasmic reticulum (for a recent review see [5]).
‘‘Noncompaction of (left-) ventricular myocardium’’ (NVM, also
designated LVNC [MIM 300183]), a recently recognized
congenital cardiomyopathy, shows typically a ‘‘spongy’’ appear-
ance of the left-ventricular myocardium. NVM was first described
in 1984 [6]. Albeit rare, it is now due to improved diagnostic
technology recognized more frequently than previously. Both,
syndromic and isolated cases have been identified [7–9]. Clinical
consequences are variable. Early onset of symptoms has been
reported [9], but others described long latency with presentation in
adults at an advanced age, generally including congestive heart
failure, ventricular arrhythmias and systemic thromboembolism
[7,10–12]. The myocardium of affected individuals is character-
ized by persisting trabeculations and deep intertrabecular recesses,
reminiscent of the cardiac muscle in the developing heart.
Accordingly, noncompaction of the ventricular myocardium has
been suggested to result from an intrauterine arrest of cardiac
development [7,13].
In family studies evidence has been obtained for genetic
heterogeneity of NVM. X-chromosomal causes have been linked
to the TAZ gene encoding taffazin [MIM 300394], also associated
with the Barth syndrome in children [MIM 302060] [9].
Autosomal mutations have been identified in LDB3, the LIM
domain-binding protein 3 gene on chromosome 10 [MIM
605906] and in DTNA on chromosome 18 [MIM 601239] [10].
LDB3 encodes ZASP, the ‘Z-band alternatively spliced PDZ motif-
containing protein’ [14]. DTNA encodes a-dystrobrevin. Other
investigations pointed to additional NVM loci with unknown
genes on chromosome 5 and 11, respectively [15,16].
Here we report on the results of a clinical and genetic analysis of
a large German family suffering from NVM. The detailed clinical
and morphologic characterization of the members of family DU-
11 afforded the identification of a disease-related genomic locus on
chromosome 14q by a genome-wide linkage analysis. Further
refinement of the disease gene region led to sequencing of two
genes, MYH6 [MIM 160710] and MYH7 [MIM 160760],
encoding the a- and b-myosin heavy chain, respectively. A
previously unknown missense mutation was detected in the gene
encoding the b-myosin heavy chain (MYH7), the predominant
myosin isoform in the ventricular myocardium. Finally, via an in
silico analysis clues to structural and functional consequences of the
mutation in the b-myosin heavy chain were obtained.
RESULTS
Clinical Findings
In order to identify all cases of noncompaction within the family
DU-11, transthoracic echocardiography (TTE) was employed (2D
mode, M mode and color Doppler imaging). NVM was observed
in three generations (fig. 1). The morphological phenotype
observed varied from apical thickening with mild trabecularization
to a spongy myocardium affecting the apical half of the left
ventricle. The sponge-like appearance of the apical myocardium
with excessive trabeculations in apex regions of both ventricles is
shown in figure 2. NVM was further confirmed by TTE in a total
of 9 patients (see table 1 and fig. 3 for echocardiographs of the
index patient and her sister’s daughter). Two deceased individuals
(II:3 and III:2) and one living child (IV:6) were considered partially
affected (see Materials and Methods).
In addition to NVM, three individuals displayed an atrial septal
defect (ASD [MIM 108800]) and Ebstein’s anomaly (EA, [MIM
224700]). One patient had NVM and ASD and one patient
showed NVM in combination with EA. All probands showed
normal thickness of the interventricular septum and of the free
ventricular wall. Signs of a canonical hypertrophic cardiomyop-
athy, such as asymmetric hypertrophy or thickening of the
interventricular septum, were not observed.
NVM in family DU-11 was generally associated with a hypoki-
neticapex(asopposedtothehyperkineticapexassociatedwithapical
HCM). As a consequence, the pump function was reduced (see
below). In contrast to the typical picture of dilated cardiomyopathy,
the end-diastolic diameter was below 55 mm in all adult probands.
The index patient (III:4) presented at the age of 39 years with
dyspnoea upon exertion. Her condition and the condition of her
sister (III:8) deteriorated within 3 years after initial presentation,
resulting in a severely reduced pump function (2.4 and 2.1 l/min,
respectively , measured using thermodilution; normal range: 4.0–
10.2 l/min). They are currently enlisted for heart transplantation.
Cardiac symptoms were also reported from the index patient’s
mother (II:3) and from her sister’s daughter (IV:13). Patient II:3
suffered from an atrio-ventricular block (AV-block) which required
implantation of a pacemaker. She died from sepsis related to a
pacemaker-associated infection. The clinical status of individual
IV:13 changed from asymptomatic to NYHA I (classification of
heart failure according to the New York Heart Association) during
follow-up. Two cases of premature death were reported from the
third generation. One member of the family died as an infant from
unknown cause (III:1), and another one as a young man at the age
of 26 years (III:2). Patient III:2 suffered from a hemodynamically
relevant defect of the atrial septum, recurrent syncopes and
cardiac death. Eight family members were clinically asymptomatic
at presentation, but had clear morphological signs of noncompac-
tion. Regarding clinical severity, there is a tendency of NVM to
develop unfavorably in adult family members. Based on the
variable and age-dependent clinical expressivity we considered a
reduced penetrance of the phenotype for further genetic analysis.
Linkage of NVM to chromosome 14q
In previous family studies, evidence has been obtained for genetic
heterogeneity of NVM[9,10,14–16]. Two of the proteins involved,
ZASP and a-dystrobrevin, are linked to the myocardial cytoskel-
eton. To identify the locus underlying NVM in family DU-11, we
performed a genome-wide linkage analysis using microsatellite
markers at a spacing of about 10 cM. We used morphological
changes as determined by echocardiography to define a total of 9
affected, 2 partially affected and 13 unaffected family members,
which we all included into the genome scan, and found significant
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dominant mode of inheritance with a reduced penetrance of 90%
for the affected individuals and of 50% for the partially affected
individuals (II:3 and IV:6) a maximum two point LOD score of
4.15 was obtained for marker D14S990 at h=0 (fig. 4A).
Calculations under the same assumptions but with a penetrance
of either 80% or 70% resulted in slightly reduced maximum LOD
scores of 3.82 and 3.53 for marker D14S990 at h=0, respectively
(data not shown). We saturated the critical region on chromosome
14 with additional markers and constructed haplotypes. Obligate
recombinants revealed a minimum common disease haplotype, i.e.
shared by all patients, ranging from 14ptel to marker D14S264
(fig. 1 and fig. 4B). The finding that proband II:3 was clinically
affected, while the two sisters who shared the same haplotype
(probands II:1 and II:2) were not, allowed to tentatively conclude
that individual II:3 was a carrier of a de novo mutation. In this
context it is worth to note that neither of the two unaffected sisters
had children which could have been analyzed for the presence or
absence of NVM. A LOD score of 3.82 (or 3.53) for the marker
D14S990 led us to suppose a mutation in either of the two myosin
heavy chain genes MYH6 or MYH7, both mapping to this region
of chromosome 14. To test this suggestion, the two genes coding
for a- and b-myosin heavy chain were subsequently sequenced.
A missensemutationin MYH7cosegregateswithNVM
The defined critical region includes the genes MYH6 and MYH7
encoding the cardiac a- and b-myosin heavy chains (MHC-a and
MHC-b), respectively. Since MHC-b is the predominant isoform
in the human ventricle [17,18], we decided to investigate in detail
MYH7 as a likely candidate gene. By sequencing the 40 exons of
MYH7 in the index patient a heterozygous single nucleotide
exchange at the position c.842G.C in exon 10 was identified. As
a consequence, a positively charged arginine is replaced by an
uncharged threonine residue at position 281 of MHC-b (R281T)
(fig. 4C). As found by pyrosequencing and restriction fragment
length polymorphism analysis, this substitution is present in all
family members affected by NVM but absent from all unaffected
family members. Thus, a perfect cosegregation between the NVM
phenotype (affected and partially affected) and the R281T
mutation was observed in our family. The absence of both the
mutation and noncompaction in two siblings who carry the same
‘‘disease’’ haplotype as their affected sister (II:3) may be explained
by a germ line mutation in one of the parents. The occurrence of a
de novo mutation in patient II:3 would provide a further strong
argument in favor of the disease-causing nature of this mutation.
To exclude a neutral polymorphic variant, 184 healthy control
individuals were tested negative for the exchange at position c.842
of MYH7. Further, it is unlikely that two other disease-causing
genes, LDB3 (encoding Cypher/ZASP) and DTNA (encoding a-
dystrobrevin), contribute to noncompaction observed in family
DU-11 since no linkage was found with either of these loci. Finally,
sequencing of the gene MYH6 did not reveal any missense or
truncation mutation in the a-myosin heavy chain gene (data not
shown). In a nutshell, we have detected a new, hitherto unknown
mutation in exon 10 of MYH7, responsible for a phenotype
previously not linked to this gene.
Assumed consequences of the R281T mutation
b-myosin is one of the principal constituents of the contractile
apparatus of ventricular myocytes. It consists of two heavy chains
and two pairs of light chains. The subfragment-1 (S1) contains the
ATPase site and an actin binding region (fig. 5A), both are crucial
Figure 1. Pedigree of family DU-11 with haplotypes on chromosome 14 and segregation of MYH7 mutation R281T (c.842G.C). Family members
are shown by filled black symbols (affected), by half filled symbols (partially affected), open symbols (unaffected) and gray symbols (unknown
affection status). An arrow points to the index patient. The disease associated haplotype is shown by filled black bars. Markers within the minimum
disease associated haplotype are boxed. Below the haplotypes of each individual the occurrence of wild-type (+) and mutant MYH7 alleles (2)i s
indicated.
doi:10.1371/journal.pone.0001362.g001
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missense mutation is located in the globular head of MHC-b and
affects a position in the vicinity of the switch I loop of the ATPase
site[19]. R281 is highly conserved in myosins, with a large
evolutionary distance ranging from insects (D. melanogaster) over
invertebrates to humans (fig. 6). It is therefore possible to discuss
the consequences of the R281T exchange by referring to crystal
structures of orthologues of human MHC-b, e.g. the S1 domain of
chicken gizzard myosin (PDB entry 2MYS, approximately 75%
sequence identity with S1 of human MHC-b)[19]. In this
structure, the position corresponding to human R281 (chicken
R283) is involved in a salt bridge with a highly conserved aspartic
acid residue (human D325/chicken D327) (fig. 5B). The salt
bridge is buried below the protein surface and anchors an a-helix
within a saddle-shaped structural protrusion on the surface of S1
(residues 275 to 330, approx.). Replacing either R281 or D325 will
lead to the destabilization of this subregion within S1. Hence it is
likely that a mutation of arginine 281 to threonine affects the
normal folding and/or the ATPase activity of b-myosin, leading to
altered contractile function of the sarcomere.
Figure 2. Imaging of NVM in patient III:8 of family DU-11. A, Magnetic resonance image: long-axis plane in diastole. Prominent myocardial
trabeculations and deep intertrabecular recesses are seen in the apical half of the right and left ventricle as indicated by arrows. B, Magnetic
resonance image: short-axis plane in diastole. In the apex region the cavum and the myocardial wall can not clearly be distinguished. Extensive
trabeculations in this region produce a sponge-like appearance of the myocardium. C, Two-dimensional echocardiograph: apical four-chamber view
in diastole with (right) and without (left) color flow imaging. A massive apical thickening is seen without any evidence of trabeculations in the left
image. In contrast, color flow imaging (right image) shows more clearly the recesses extending deeply into the myocardial wall. D, Two-dimensional
echocardiograph: parasternal short-axis view in diastole with (right) and without (left) color flow imaging. The left image shows a mesh-like
morphology in the mid-region of the left ventricle. The cavum is not clearly discernable. The right image demonstrates numerous small blood-flow
eddies within the sponge-like myocardium (as shown by color flow imaging). LV, left ventricle; RV, right ventricle; LA, left atrium; RA, right atrium.
doi:10.1371/journal.pone.0001362.g002
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protein can culminate in a similar condition like mutations that
affect cytoskeletal components. Further, it remains unclear, why
R281T–in contrast to all other known MYH7 mutations–causes
NVM rather that HCM or DCM. Mutations associated with
HCM and DCM are clustered in four functionally important
regions: the actin-myosin interface, the ATPase active site with the
ATP binding region, the essential light chain (ELC) binding
interface and the rod (fig. 5A) [20]. In contrast to all other HCM
or DCM mutations known so far, the R281T substitution is
localized in exon 10. Hence, it will be interesting to see whether
other mutations in the same exon cause a similar phenotype.
DISCUSSION
In the present study, we have linked noncompaction of the
ventricular myocardium to a mutation in the b-myosin heavy
chain gene. Despite the fact that a typical ‘‘HCM/DCM gene’’
was affected, none of the mutation carriers showed signs of
canonical hypertrophic or dilated cardiomyopathy. Rather, some–
but not all–mutation carriers had congenital heart disease, namely
Ebstein’s anomaly, i.e. a dislocation of the tricuspid valve, and/or
an atrial septal defect. Thus, the R281T substitution was linked to
either an isolated or non-isolated form of NVM that–in this
family–did not develop into HCM or DCM.
The clinical consequences of the R281T mutation were diverse.
Symptomsweregenerallyabsentinchildhoodand adolescence. One
caseofcardiacdeathinearlychildhood (III:1)mayhavebeenrelated
to disease transmitted in this family, but no data exist. In two sisters
of the third generation (III:4 and III:8) symptomsdeterioated rapidly
in the third and fourth decade of life, while one of their brothers
(III:6) was at initial presentation asymptomatic, but he was identified
as affected by noncompaction and also as carrier of the MYH7
mutation. (Note, this proband later declined follow-up investiga-
tions.) An older brother of the two affected sisters (III:2) died (in the
80s) from cardiac death at age 26. No clinical data as to details of his
cardiac conditon are available, nor was he genotyped. It does not
seem unlikely to us, however, that he was also a carrier of the
mutation detected inhis first-degree sibs. Noncompaction was in our
family clearly identified in early childhood. The youngest NVM
carrier was 7 years old at the time of diagnosis. Hence, in agreement
with others we conclude that NVM was present at birth [12].
Otherwise, symptoms developed later in life, strongly suggesting an
age-dependent penetrance of the condition in family DU-11.
We hypothesize, that two nosological effects may be superim-
posed in the affected members of the family. One of them,
noncompaction may have mild consequences, at least early in life.
The second effect may result from the suggested structural change
of the cardiac myosin heavy chain which possibly leads to an
altered contractile function causing phenotypic consequences later
in life. If a myosin-related dysfunction was involved, it did,
however, not induce myocardial hypertrophy or chamber
dilatation, the structural hallmarks of HCM and DCM, respec-
tively. Congenital malformations such as Ebstein’s anomaly or
atrial septal defect, as seen in some family members, may have
further contributed to the symptoms.
A key question is whether a mutation in a contractile protein
(such as the b-myosin heavy chain) can trigger defects in both
compaction of the myocardium and septation of the atria. In this
context it is noteworthy that our results are essentially in line with
three recent reports demonstrating, that mutations in myosin
heavy chain genes can have damaging effects on the cardiovas-
cular development in humans. A missense mutation, I820N, in
MYH6, which codes for predominantly atrial a-myosin heavy
chain (MHC-a) results in incomplete atrial septum formation. A
similar effect was observed in developing chicken atria upon
knock-down repression of MYH6 using oligonucleotides comple-
Figure 3. Imaging of NVM in the index patient (III:4, panel A) and her sister’s daughter (IV:13, panel B). Shown are two-dimensional
echocardiographs (ventricular part of a four-chamber view) in diastole, with (right) and without (left) color flow imaging. Arrows point to recessesi n
the myocardial wall.
doi:10.1371/journal.pone.0001362.g003
Table 1. Patient Characteristics (initial presentation)
......................................................................
Patient Age
a Sex Clinical Status
b EA
c ASD
d aECG
e NVM
f
II-3 dc F HF-NYHA III ++ + (+) non-isolated
dc at 61 years
due to sepsis
III-2 dc M CD at 26 years ++ + (+) non-isolated
III-4 39 F HF-NYHA III-IV ++ + + non-isolated
III-6 38 M asymptomatic - - - + isolated
III-8 36 F HF-NYHA I - - - + isolated
IV-3 13 M asymptomatic + - ++ non-isolated
IV-4 18 M asymptomatic - - ++ isolated
IV-5 14 M asymptomatic - - ++ isolated
IV-6 11 M asymptomatic - - + (+) isolated
IV-7 10 M asymptomatic - - ++ isolated
IV-8 7 F asymptomatic - - ++ isolated
IV-13 7 F asymptomatic - ++ + non-isolated
aAge at presentation in years; dc, deceased;
bHF, chronic heart failure; NYHA, classi-fication of heart failure according to the
New York Heart Association; CD, cardiac death
cEA, Ebstein’s anomaly;
dASD, atrial septal defect;
eaECG, abnormal ECG;
fNVM, non-compaction of the ventricular myocardium; +, affected; (+), partially
affected; see Material and Methods for details on the affection status; non-
isolated/isolated: with/without EA and/or ASD. Listed are all carriers of the
MYH7 mutation and in addition individual III-2 who was not genotyped.
doi:10.1371/journal.pone.0001362.t001
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PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1362Figure 4. Genetic analysis. A, Linkage analysis. Two-point LOD scores for all chromosomes under the assumption of a reduced penetrance of 90% are
shown. In the line below the diagram each red slash indicates the position of an analyzed marker on the corresponding chromosome. B, Genetic map
of the candidate region 14cen-14q12. A part of the deCODE map is shown in the upper part. The critical interval is delimited by 14ptel and D14S264.
The genomic organization of MYH7 is delineated in the lower part. Exons are indicated by filled boxes and introns by horizontal lines. The
translational start codon is located in exon 3. The positions of the intragenic markers MYO I in intron 1and MYOII in intron 24 are shown. The mutation
was identified in exon 10. C, Mutation analysis. Chromatograms of the index patient III:4 and her unaffected son IV:2 are shown. The mutation site is
marked by an arrow. Parts of the nucleotide sequence (from c.835 to c.849) and protein sequence (from 279 to 283) are given below.
doi:10.1371/journal.pone.0001362.g004
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PLoS ONE | www.plosone.org 6 December 2007 | Issue 12 | e1362mentary to MYH6 mRNA, suggesting that an altered MHC-a
structure or lack of this protein contribute to congenital heart
disease [21]. Since the b-isoform of myosin heavy chain is also
present in atria, albeit at rather low levels [22], one has to consider
the possibility, that a mutation in MYH7 can also provide the basis
for the development of ASD. Secondly, in a separate study, various
mutations in MYH3 [MIM 160720] encoding embryonic myosin
heavy chain have been causally linked to the occurence of the
Freeman-Sheldon syndrome [MIM 193700] and the Sheldon-Hall
syndrome (alternatively designated type 2B distal arthrogryposis
[MIM 601680]). These syndromes are characterized by congenital
manifestation of severe isolated or multiple contractures. It was
proposed, that dysfunctional force production in myofibers in an
early stage of embryogenesis was responsible for these symdromes
[23].Ina third study,mutations inMYH11 [MIM160745],thegene
coding for smooth muscle (SM) myosin heavy chain were shown to
trigger patent ductus arteriosus as a congenital trait and the
formation ofthoracic aortic aneurysms oraorticdissectionsinadults.
Figure 6. Multiple alignment of different myosin molecules. The interacting sites R281 and D325 (both in bold, position numbering according to
MYH7_HUMAN) are highly conserved between myosin molecules of human, fruit fly, zebrafish and Caenorhabditis elegans, respectively (*, identical
position; :, conservative exchange). Sequence names correspond to SwissProt entry names: MYH7_HUMAN-human myosin heavy chain, cardiac
muscle beta isoform; MYH1_HUMAN-human myosin heavy chain, skeletal muscle, adult 1; MYH4_HUMAN-human myosin heavy chain, skeletal
muscle, fetal; MYH1_MOUSE-murine myosin heavy chain, skeletal muscle, adult 1; MYH4_RABIT-rabbit myosin heavy chain, skeletal muscle, juvenile;
MYSS_CHICK-chicken myosin heavy chain, skeletal muscle, adult; Q802Z4_BRARE (Q802_BRARE)-zebrafish protein Q802Z4; MYSA_DROME-fruit fly
myosin heavy chain, muscle; MYO3_CAEEL-Caenorhabditis elegans myosin heavy chain A.
doi:10.1371/journal.pone.0001362.g006
Figure 5. Localization of R281 in a protein model of the myosin heavy chain. A, Positions of amino acids affected in NVM, HCM and DCM. The
mutations were plotted on a model of chicken skeletal myosin subfragment-1 (PDB code 2MYS). Functional sites are indicated by arrows. 68 selected
mutations causing HCM are indicated by yellow spheres and 4 mutations causing DCM by green spheres. The mutations were selected from the
UniProt database (UniProtKB) and from two publications[33,34]. The described NVM causing mutation is highlighted as a blue sphere and labeled
according to the position in MYH7_HUMAN. B, Close-up view of the salt bridge between residues R281 and D325 in chicken skeletal myosin
subfragment-1 (PDB code 2MYS). The amino acids are numbered according to MYH7_HUMAN. The sulfate molecule (yellow and orange) marks the
ATPase active site for better orientation. The residues R281 and D325 are shown according to the CPK color scheme (grey, carbon atoms; red, oxygen
atoms, i.e. acidic side chain; light blue, nitrogen atoms, i.e. basic side chain). The salt bridge between R281 and D325 is symbolized by dashed black
lines that indicate potential hydrogen bonds. The helix attached to D325 is highlighted in red.
doi:10.1371/journal.pone.0001362.g005
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improper coiled-coil formation of the SM myosin rod [24]. Taken
together, these data argue in favor of a general role of the myosin
heavy chain in the development of the cardiovascular system.
In conclusion, our data suggest that a mutation in the b-myosin
heavy chain causes noncompaction of the ventricular myocardium
associated with a variable expressivity of the disease. The
combination of an ‘old’ gene with a ‘new’ phenotype may help
to unravel causes, mechanisms and clinical implications of NVM.
Note added in proof
In the course of the review process, three different manuscripts
have been published that link defects in sarcomeric proteins to
noncompaction of the ventricular myocardium (Monserrat et al.,
European Heart Journal, 2007; Hoedemaekers et al., European
Heart Journal, 2007; Kaneda et al., Clinical Science, 2007).
However, the present work is the only one that shows linkage of
the disease gene region to noncompaction in a genome-wide
analysis.
MATERIALS AND METHODS
Clinical evaluation
The clinical and genetic studies were carried out according to
institutional guidelines after approval of the local ethics committee
(Ethics Committee of the University of Witten/Herdecke) and
given informed consent from all participants. Twenty four
members of family DU-11 were clinically evaluated by a review
of their medical history, physical examination, 12-lead echocar-
diography (ECG) and 2-dimensional transthoracic echocardiogra-
phy (TTE). Echocardiographic measurements of wall thickness
and cavity dimensions were performed using M-mode and 2-
dimensional views. NVM was identified based on the following
diagnostic criteria [12,25]: Presence of prominent multiple
trabeculations, deep recesses in the thickened myocardium filled
with blood from the ventricular cavity (as visualized by color
Doppler imaging), presence of a two layered structure of the
endomyocardium with a thin compacted layer and a thick non-
compacted layer. The NVM affection status was classified as
follows: unknown, deceased individuals and/or no clinical records
available; unaffected, absence of a non-compacted myocardial
layer; partially affected, documented apical thickening (,18 mm)
due to noncompaction with a ratio of non-compacted/compacted
myocardium (N/C ratio) of either ,2 or not quantifiable; affected,
apical thickening (.18 mm) due to noncompaction with a N/C
ratio $2. We note, that neither the partially affected nor the
affected patients showed signs of canonical hypertrophic cardio-
myopathy (see Results section). The NVM status of individual III:8
was confirmed by magnetic resonance tomography (MRT).
Ebstein’s anomaly was diagnosed echocardiographically based
on the dislocation of the septal leaflet of the tricuspid valve from
the insertion of the anterior leaflet of the mitral valve towards the
apex by $8 mm/m
2 body surface area [26]. EDTA-blood was
taken from 24 members of family DU-11, and DNA was available
from 184 healthy volunteers.
Linkage analysis and sequencing
DNA was extracted from peripheral blood samples using standard
methods. A genome-wide scan with a set of 430 polymorphic
microsatellite markers (modified Weber9-set, Marshfield Institute),
average spacing of about 10 cM, was performed. Additional
markers including two microsatellites in the MYH7 gene (one in
the promotor region, MYO I, and one in intron 24, MYOII (ref.
[27], [28]) , were used for fine mapping. Products of PCR assays
with fluorescently labeled primers were analyzed by automated
capillary genotyping on a MegaBACE 1000 (GE Healthcare
Biosciences, Piscataway, NJ) and scored using the Genetic Profiler
analysis software (GE Healthcare Biosciences, Piscataway, NJ). A
two-point linkage analysis was performed using the program
SuperLink of easyLINKAGE Plus (version 5.02) [29] assuming an
autosomal dominant model of disease inheritance with a disease
allele frequency of 0.001, equal female and male recombination
rates and two liability classes. The penetrance values were set at
0.9, 0.8 or 0.7 for the affecteds (liability class 1) and at 0.5 for the
partially affected (II:3 and IV:6), respectively. Haplotypes were
reconstructed using SIMWALK2 (version 2.91) [30]. Bidirectional
sequencing of all coding exons and splice sites of the human genes
MYH6 and MYH7 was carried out for the index patient III:4 of
family DU-11. The primer sequences were obtained on the basis
of reported nucleotide sequences [31] and the Genbank entry
NT_026437. Sequencing was performed according to the Dye
Terminator Cycle Sequencing Quick Start Kit protocol (Beckman
Coulter, Fullerton, CA) on a CEQ 8000 XL DNA Sequencing
System (Beckman Coulter, Fullerton, CA). Sequences were
analyzed and aligned using the CEQuence Investigator program
(Beckman Coulter, Fullerton, CA). In the other members of the
family only MYH7 exon 10 was sequenced to determine the
occurrence of the R281T mutation. Healthy controls were
analyzed by pyrosequencing for the presence or absence of the
R281T mutation in MYH7 exon 10. Pyrosequencing was
performed as described previously [32].
Protein modeling
Protein models were derived from the RCSB Protein Data Bank
(see below). The ribbon plots were drawn using the program
ViewerPro version 4.2 (Accelrys Inc., San Diego, CA) and
PyMOL Molecular Graphics System (Delano Scientific, San
Carlos, CA).
Protein alignment and accession numbers
Multiple sequence alignments were performed with the ClustalW
program.
Genbank: Homo sapiens chromosome 14 genomic contig,
reference assembly (MYH6 and MYH7), NT_026437; Homo sapiens
heavy polypeptide 7, cardiac muscle, beta (MYH7), NM_000257;
RCSB Protein Data Bank (PDB): chicken skeletal muscle myosin
subfragment-1, 2MYS; UniProtKB: human myosin heavy chain,
cardiac muscle beta isoform, P12883; SwissProt entry names:
MYH7_HUMAN-human myosin heavy chain, cardiac muscle
beta isoform; MYH1_HUMAN-human myosin heavy chain,
skeletal muscle, adult 1; MYH4_HUMAN-human myosin heavy
chain, skeletal muscle, fetal; MYH1_MOUSE-murine myosin
heavy chain, skeletal muscle, adult 1; MYH4_RABIT-rabbit
myosin heavy chain, skeletal muscle, juvenile; MYSS_CHICK-
chicken myosin heavy chain, skeletal muscle, adult;
Q802Z4_BRARE (Q802_BRARE)-zebrafish protein Q802Z4;
MYSA_DROME-fruit fly myosin heavy chain, muscle; MYO3_-
CAEEL-Caenorhabditis elegans myosin heavy chain A.
Web Resources
URLs for data presented herein are as follows:
GenBank, http://www.ncbi.nih.gov/Genbank/index.html
RCSB Protein Data Bank, http://www.rcsb.org/pdb/Wel-
come.do
UniProtKB/Swiss-Prot DATABASE, http://www.ebi.ac.uk/
swissprot/
OMIM, http://www.ncbi.nlm.nih.gov/Omim/
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